K-679 / Kowa - LARVOL DELTA

Hepatocyte ApoJ accelerates injury-induced liver fibrosis by activation STAT3 through Ranbp2 mediated-SUMOylation. (PubMed, Cell Mol Gastroenterol Hepatol) - "ApoJ plays a pivotal role in accelerating the progression of liver fibrosis. Therapeutic strategies targeting the ApoJ/STAT3/RanBP2 axis may offer a novel approach for the prevention and treatment of fibrotic liver diseases."

Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • CLU • RANBP2 • STAT3 • TGFB1

K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs (AACR 2025) - "Using this platform, we developed K-679, which combines cetuximab with DM1-loaded unimicelles. Antigen-binding specificity and cellular internalization of K-679 were evaluated using surface plasmon resonance, flow cytometry, and fluorescence microscopy. Our findings establish K-679 as a promising therapeutic candidate for heterogeneous EGFR-expressing solid tumors, characterized by a more potent anti-tumor effect through an exceptionally high DAR, enhanced drug accumulation into tumors and significant bystander effect."

Oncology • Solid Tumor • EGFR

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors (PRNewswire) - "Kowa Company...today announced an upcoming presentation of non-clinical data for K-679...The compound, developed using Kowa's proprietary micelle technology, has demonstrated superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25th-30th, 2025 in Chicago, Illinois."

Preclinical • Solid Tumor